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A B S T R A C T
The pharmacological class of β-blockers includes a plea of molecules with largely different pharmacokinetic and
pharmacodynamic characteristics with a protective effect that may span far beyond the cardiovascular system.
Although all these compounds share the pharmacological blockade of the adrenergic receptors, each of them is
characterized by specific pharmacological properties, including selectivity of action depending on the adrenergic
receptors subtypes, intrinsic sympathomimetic activity (ISA), lipid solubility, pharmacokinetic profile, and also
other ancillary properties that impact their clinical effect. Their use in the treatment of hypertension has been
extensively debated and at the moment a class indication is not present. However, in specific niche of patients,
such as in those young individuals in which hypertension is mainly driven by a sympathetic hyperactivation,
strong evidence pose β-Blockers as a highly reasonable first-line treatment. Lipophilic β-blockers, specifically
propranolol and metoprolol, can cross the Blood Brain Barrier and have a Class A indication for the prophylactic
treatment of migraine attacks. Moreover, since β-adrenergic receptors affect the proliferative process of both
cancer and immune cells, their blockade has been associated with metastasis reduction in several epithelial and
solid organ tumors posing β-Blockers as a new attractive, inexpensive and relatively safe therapeutic strategy in
patients with several types of cancer. However, further dedicated prospective, randomized, placebo-controlled
studies are needed to determine the real efficacy of these compounds.
1. Introduction
The pharmacological class of β-blockers include a plea of molecules
with largely different pharmacokinetic and pharmacodynamic char-
acteristics, whose clinical indications stemmed from large randomized
clinical trials. Despite they have been in clinical use since more than
three decades, new indications are still emerging.
In the present review, we will re-assess their clinical usefulness in
cardiovascular medicine, focusing on hypertension in which their role
is widely debated, and discuss the most recent evidence of their po-
tential extra cardiovascular effects.
2. Pharmacology of β -blockers
β-adrenergic receptor-blocking agents (β-blockers) are among the
most widely used classes of drugs in clinical practice. They are com-
petitive antagonists of adrenergic receptors, that can be distinguished
for their selectivity profiles versus β-1 and β-2 receptors, the presence
of intrinsic sympathomimetic activity, differences in lipid solubility that
affects penetration into the central nervous system (CNS), inverse
agonist properties, capacity to induce vasodilation and, finally, for their
specific pharmacokinetics parameters. Three generations of β-blockers
have been developed and entered into the clinical practice over time.
The first generation includes only non-subtype-selective drugs, such as
propranolol, which have similar affinity for β-1 and β-2 receptors.
Second generation includes β-1 selective drugs, such as atenolol, biso-
prolol and metoprolol. Third generation contains both selective and
non-selective β-1 subtype drugs that possess additional properties, such
as the antagonism on the α-1 receptor or the capability of inducing
nitric oxide (NO) production, which are properties to be taken into
account to optimize their use in the clinical practice.
2.1. β-1 versus β-2 selectivity
β-1 receptors are mainly expressed in the heart, where they induce
positive chronotropic, dromotropic, bathmotropic and inotropic effects
[1], in the juxtaglomerular cells, where they control renin release, and
in the CNS, along with β-2 receptors, where they can mediate
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cardiovascular responses.
β-2 receptors are mainly expressed in different types of smooth
muscle cells located in vessels, especially those in skeletal muscle cells,
and visceral hollow organs, such as bronchi or uterus, where they
mediate smooth muscle relaxation.
The research of selective β-1 blockers stemmed from the need of
avoiding adverse effects on the respiratory tracts and on vascular tone,
and although the selectivity is not absolute, β-1 selective blockers, such
as atenolol, bisoprolol and metoprolol, are better tolerated in patients
with asthma and peripheral artery disease. However, as said, selectivity
is not absolute, but relative and therefore dose-dependent (Table 1).
β-2 receptors are also expressed, at a lower level (4:1 β-1/ β-2 re-
ceptors), in the normal heart, where they are supposed to participate in
sympathetic responses, since they are normally coupled to the Gs, with
the production of cAMP. In chronic heart failure (CHF), β-1 stimulation
is known to cause apoptosis of cardiac cells, whereas β-2 stimulation
seems to have an anti-apoptotic and proliferative effect, due to a shift of
coupling from Gs to Gi.
2.2. Intrinsic sympathomimetic activity
Some of the β-blockers, first of all pindolol, but also acebutolol,
carteolol and celiprolol, are capable of stimulating β-1 receptors in the
absence of catecholamine. These are partial agonists with intrinsic
sympathomimetic activity that become functional antagonists in the
presence of high concentrations of noradrenaline and adrenaline.
This residual agonistic activity may prevent severe bradycardia and
negative inotropy in a resting heart. Nevertheless, it is still unclear
whether this property is disadvantageous in specific clinical conditions,
such as in the secondary prevention of myocardial infarction or in
migraine.
2.3. Inverse agonistic properties
Receptors can exist in different conformational states. In the sim-
plest view, most of them are in the inactive state and become activated
upon agonist binding. However, many receptors possess basal sponta-
neous activity and can be activated, triggering transduction cascade,
even in the absence of their agonist (Table 1).
β-1 receptors display basal spontaneous activity. This means that at
rest, heart, juxtaglomerular cells, rostral ventro-lateral medullar
(RVLM) neurons (see below) can be partially stimulated in the absence
of catecholamines. Neutral competitive antagonists are drugs that
prevent the binding of the endogenous agonist, but do not affect re-
ceptor spontaneous activity, whereas inverse agonist are drugs capable
of inhibiting basal activity [2]. Inverse agonistic properties of β-
blockers might be relevant in clinical practice. It is well known that
excessive activation of cardiac β-1 receptors in response to catechola-
mines can cause deleterious effects such as cardiac hypertrophy, myo-
cytes apoptosis, fibroblast hyperplasia, and arrhythmias. However, also
constitutive activity of β-1 receptors can cause persistent deleterious
signaling to cardiomyocyte in a decompensating heart, thus suggesting
that, compared to neutral antagonist, inverse agonist may exert greater
protective effects. β-blockers with inverse agonist properties are me-
toprolol, carvedilol, propranolol and bisoprolol, whereas pindolol is
considered a neutral antagonist. Their inverse agonist activity has been
studied in different experimental models: cell culture, tissues, isolated
heart, producing slightly different results in terms of efficacy [2]. In
human atrial and ventricular myocardium the established rank order is:
metoprolol > bisoprolol= nebivolol= carvedilol > bucindol [3].
2.4. Vasodilation
Some β-blockers are capable of inducing vasodilation, an ancillary
property that can be useful in the treatment of both CHF and hy-
pertension. In particular, nebivolol can stimulate NO production from
endothelial cells, apparently through an involvement of β-3 receptors.
Carvedilol has an antagonist activity on α-1 receptor which is re-
sponsible for vasodilation (Table 1). However, recent data would sug-
gest that vasodilation by nebivolol and carvedilol might be the con-
sequence of biased agonism.
2.5. Biased agonism
Activated and phosphorylated G-Protein Coupled Receptors (GPCR),
such as adrenergic receptors, can recruit a class of multifunctional
proteins, β -arrestins, which are known to play a central role in receptor
desensitization. In the last few years a new paradigm has emerged
suggesting that β -arrestins can also mediate downstream signaling on
their own by scaffolding various components of different signaling
cascades. The recruitment and the signaling of β -arrestins is completely
independent from other receptor functions, such as the ability of
modulating the production of classic second messengers, and can occur
as unique receptor response. Synthetic ligands capable of selectively
Table 1
Main pharmacological properties of commonly used β-blockers.
DRUG ISA LIPID SOLUBILITY VASODILATION BIOAVAILABILITY % PLASMA T 1/2 h
FIRST GENERATION: non-selective β-blockers
Nadolol 0 Low 0 30 20-24
Penbutolol + High 0 90 5̴
Pindolol +++ Low 0 90-100 3-4
Propranolol 0 High 0 30 3-5
Timolol 0 Low 0 75 4
SECOND GENERATION. Selective β1-blockers
Acebutolol + Low 0 30-50 3-4
Atenolol 0 Low 0 40-50 6-7
Bisoprolol 0 Low 0 80 9-12
Esmolol 0 Low 0 – 0,15
Metoprolol 0 Moderate 0 40-50
THIRD GENERATION WITH ADDITIONAL PROPERTIES: non selective β-blockers
Carteolol ++ Low YES 90 6
Carvedilol 0 Moderate YES 25-35 7-10
Labetalol + Low YES 25-35 3-4
THIRD GENERATION WITH ADDITIONAL PROPERTIES: selective β1- blockers
Betaxolol 0 Moderate YES 80 15
Celiprolol + Low YES 30-70 5
Nebivolol 0 Low YES – 11-30
Abbreviations: ISAIntrinsic Sympathetic Activity; T½ hplasma half time.
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inducing β -arrestin recruitment and signaling have been identified and
described for several GPCRs and are referred to as biased agonists. It
has been recently demonstrated that nebivolol and carvedilol, by se-
lectively activating the pathway of β-arrestin and ERK may stimulate
the expression and the activity of eNOS [4,5]. Other β-blockers might
have biased agonist activity and novel pharmacological properties may
depend on it (Fig. 1).
2.6. Pharmacokinetic properties
β-blockers show gross differences in term of absorption, metabo-
lism, bioavailability, protein binding and half-life [6]. These different
properties influence drug dose, dosing intervals, and appropriateness in
patients with renal or hepatic disease, but a detailed discussion of these
differences is out of the purposes of this review.
2.7. Lipid solubility
Lipid solubility has been considered a detrimental property of β-
blockers. Indeed, β-1 receptors are expressed in several areas of the
CNS, but their accessibility is restricted by the brain-blood barrier
(BBB), which is more permissive to lipophilic drugs. Many CNS adverse
drug reaction of the most lipophilic β-blocker, propranolol, which in-
clude hallucination, vivid dreams, depression, can be explained by ex-
cessive penetration into the CNS.
However, β-1 receptors are also expressed on the RVLM neurons,
which are part of the cardio-regulatory and vasomotor centers of me-
dulla oblongata. The activation of β-1 receptors stimulate these neurons
that, in turn, increase the sympathetic outflow. Therefore, a moderate
lipid solubility may be functional to the passage of the drug through
BBB and blockade of β-1 receptors in the CNS [7].
This additional pharmacological property might be useful in arterial
hypertension characterized by a sympathetic hyperactivity (see below)
or in cardiac tachyarrhythmia. Among β-1 selective agents, metoprolol
and carvedilol are those with moderate lipid solubility (Table 1).
3. β-blockers and hypertension
Current American guidelines (Joint National Committee VIII) [8]
place β-blockers as a third therapeutic choice for the treatment of hy-
pertension and similarly, the NICE guidelines state that β-blockers are
not a preferred initial treatment [9]. The only exceptions in which such
class of drugs may be considered are for patients intolerant to ACE-Is
and angiotensin II receptor blockers (ARBs), for women of childbearing
potential, and for subjects with evidence of increased sympathetic drive
[8,9]. On the contrary, ESC/ESH guidelines do not exclude β-blockers
as one of the options for fist-line antihypertensive treatment [10] and
suggest their use in specific conditions associated with hypertension,
such as previous myocardial infarction, angina pectoris, CHF and atrial
fibrillation. Moreover, several meta-analyses (including patients in a
40–85 years age range) have concluded that β-blockers are
Fig. 1. Signal transduction triggered by classic or biased agonists.
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inappropriate first-line agents in the treatment of hypertension [11,12],
highlighting they are less effective in reducing cardiovascular events
and possibly associated with an increased risk of stroke in the elderly
(Table 2). However, since the pathophysiology of primary/essential
hypertension differs in elderly and younger subjects, the latter being
closely linked to obesity and increased sympathetic nerve activity, the
efficacy of β-blockers in the younger/middle-aged group in reducing
the risk of death, and cardiovascular end-points might be greater with
respect to other first-line recommended treatments. Therefore, two re-
cent meta-analyses evaluated the efficacy of β-blockers in the reduction
of cardiovascular end-points according to patients’ age [13,14]. Khan
et al. analyzed 17 studies, including eight randomized placebo-con-
trolled studies and nine trials involving active hypertensive agents [13]
(Table 2). In the younger/middle aged hypertensive subjects (mean
age< 60 years), β-blockers were significantly superior to placebo in
reducing the risk of death/stroke/myocardial infarction, while in el-
derly patients there was with only a positive trend. Kuyper et al. [14]
involved 21 studies, comprising the same 17 studies included by Khan
et al. [14] plus an extra four studies evaluating patients< 60 years (3
studies compared propranolol with diuretic, and the fourth – AASK
study [15], compared metoprolol with amlodipine and ramipril in Black
American hypertensives with renal disease) (Table 2). The conclusion
was that in the young/middle-aged (< 60 years old) subjects both
atenolol and non-atenolol β-blockers were similarly effective in redu-
cing cardiovascular end-points, while in the elderly, atenolol (no other
β-blocker had been studied) was associated with an increased risk of
stroke [14]. The second meta-analysis did not include the most recent
follow-up results of the AASK study [16] in younger/middle-age sub-
jects, which showed that metoprolol, amlodipine, and ramipril were
similarly effective in reducing cardiovascular outcomes after a 4-year
follow-up. These differences can be explained by the fact that diastolic
(with or without systolic) hypertension, in contrast to isolated systolic
hypertension, occurs primarily in younger subjects, and is linked to
overweight/obesity and increased sympathetic nerve activity [17]. In
such subgroup of patients, a decrease in heart rate tends to be com-
pensated by a parallel increase in stroke volume, which will elevate
systolic but decrease diastolic BP [17]. In younger/middle-aged hy-
pertensives, high plasma norepinephrine levels are linked (independent
of blood pressure) to an increased risk of future cardiovascular events
and death [18]. High resting heart rates (a surrogate of high sympa-
thetic nerve activity) likewise predict premature all-cause death, cor-
onary heart disease and cardiovascular events in younger hypertensives
[18]. In younger/middle-aged hypertensives, antihypertensive agents
that increase sympathetic nerve activity (diuretics, dihydropyridine
calcium channel blockers, and ARBs) do not decrease (and may in-
crease) the risk of myocardial infarction, and are therefore in-
appropriate first-line agents in this subset [19]. By contrast, β-blockers
have been shown (vs. placebo or diuretics) to reduce the risk of myo-
cardial infarction by 35–50 %, and of stroke by 50–55 % (vs. placebo),
in non-smoking hypertensives younger than 60 years of age [20].
Atenolol was at least as effective as the ACE-inhibitor captopril in re-
ducing all cardiovascular endpoints (including stroke, which was re-
duced by 50 %), vs. less strict control of blood pressure, in obese hy-
pertensives with type-2 diabetes [21]. After 20 years of follow-up,
atenolol was significantly (23%) superior to the ACE-inhibitor in re-
ducing the risk of all-cause death (on this regard, one may hypothesize
that pleiotropic, anti-cancer properties of β-blockers discussed below,
contribute to this protective effect) [22].
Lastly, since all guidelines recommend that life style interventions,
such as physical exercise, should be the first-line treatment of hy-
pertension [23–25], β-blockers play an additional pivotal role, since
they are able to control the BP response to physical exercise better than
other antihypertensives [26,27]. Such aspect should be taken into
consideration when planning treatment for young and middle-aged
physically active hypertensive patients.
Thus, we are convinced that international guideline should re-
appraise β-blockers as highly reasonable first-line treatment of hy-
pertension in younger/middle-aged subjects (certainly, in non-smoker,
younger men), particularly in those who are obese and with evident
sympathetic activation.
4. Protective effects beyond the CV system: New therapeutic
opportunities in cancer and migraine
4.1. β-blockers and cancer: pre-clinical evidence
Evidence from pre-clinical studies suggests that β-blockers may
exert a protective role in cancer patients by altering the tumor micro-
environment and acting against disease progression and metastases.
Indeed, β-adrenergic receptors can be detected on both cancer and
immune cells, where they can affect both the proliferative processes
and multiple signaling pathways involved in cancer invasion, cancer-
associated inflammation, angiogenesis and lymphangiogenesis. In par-
ticular, invitro experiments have shown that norepinephrine is a potent
inducer of migratory activity in cell lines of colon, prostate, ovarian and
breast cancer and, conversely, blockade of β-adrenergic receptors may
favorably modulate immune response and cytokine regulation [28–31].
Importantly, in vivo studies that explored β-adrenergic receptors path-
ways suggest a key role of β-2 receptors in modulating tumor patho-
physiology.
Increasing clinical evidence suggests that nonselective compounds,
such as propranolol, may have comparable or even greater protective
effects than non-selective agents. In general, adrenergic receptors are
overexpressed in many epithelial cancers, including colorectal, lung,
thyroid, gynecological and urothelial neoplastic lesions. In addition,
matching early evidence collected in invitro migration studies, data
from the literature suggest that non-selective β-blockers may positively
affect young patients diagnosed with a wide range of epithelial cancers
(i.e. colorectal, ovarian, prostate, squamous cell carcinomas, etc.) [32].
4.1.1. β-blockers and cancer: clinical evidence
Despite encouraging pre-clinical data, knowledge of an association
of β-blocker use and cancer prognosis is still limited and somewhat
inconsistent, likely reflecting the paucity of available literature and a
heterogeneous sensitivity of different cancer subtypes to β-blocking
modulation. Even though specifically designed randomized clinical
trials would be needed, observational and case-control studies have
shown that exposure to β-blockers is associated with a reduced pre-
valence of disease recurrence and a lower cumulative rate of cancer-
related mortality in malignant melanoma [33] and breast cancer.
However, other studies failed to show a positive association of β-
blockers with improved overall survival: thus, at present, the efficacy
and benefits of anti-proliferative therapies with β-blockers has been
quantified and weighed against three major endpoints, namely cancer
recurrence, disease-free survival, and cancer-specific survival. Inter-
estingly, beside differences in cancer types, other factors such as study
design (e.g. retrospective vs. prospective) [34] and immortal time bias
(ITB, i.e. when a period exists during which the outcome of interest for
one of the cohorts cannot possibly occur because of the study design)
[35] have been advocated for justifying the large differences in cancer-
related outcomes. In addition, as highlighted in many large systematic
reviews and meta-analyses, while it is still unclear which adrenergic
receptors are involved in cancer biology, the majority of investigations
so far have been conducted with β1-selective drugs, such as metoprolol
or bisoprolol, while non-selective compounds, like propranolol, were
only used in a limited number of studies [34,36–39].
4.1.2. Cancers that may benefit from β-blocker therapy
Several investigations and pooled meta-analyses have shown that,
while β-blockers may not have direct effects on cancer occurrence, they
may be significantly associated with long-term cancer-specific survival
8 and improve disease-free survival in ovarian cancers, breast cancer,
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pancreatic cancer and melanoma [34]. In particular, a trend towards an
improved disease-free survival with non-selective β-blockers was noted
for melanoma, where the use of propranolol at the time of diagnosis
was inversely associated with disease recurrence (with an 80% risk
reduction) [33,40], and for ovarian cancer, in which β-blocker use
correlated with a 6-month longer median survival [41]. Early and
perioperative use of non-selective β-blocker propranolol, alone or in
combination with anti-inflammatory drugs, was shown to have sy-
nergistic beneficial effects on top of optimal medical and surgical
treatment in patients treated for breast cancer, preserving anticancer
immunological profiles and reducing epithelial-to-mesenchimal transi-
tion and prometastatic transcription factors [34,40,42–44]. Other stu-
dies support the use of β-blockers for pancreatic adenocarcinoma,
particularly in those patients who manifested a localized disease
[36,45]. Interestingly, in this case, no clear difference was observed by
β-blocker receptor selectivity.
Finally, non-selective β-blockers proved to be a clear possibility in a
range of other vascular cancers, including angiosarcomas, in which
these drugs significantly prolonged progression-free survival [46–48],
and retinal haemangioblastomas in von Hippel-Lindau disease, where
propranolol titrated to 120mg daily stabilized tumors and prevented
new lesion development [49].
However, other studies of lung, endometrial, prostate, and head-
and-neck cancers did not obtain any clinically meaningful evidence for
an association of β-blockers use and survival, after excluding studies
with a possible immortal time bias [34,38,50].
However, even in the absence of randomized, double-blind, pla-
cebo-controlled clinical trials, all these data collectively support the
idea of β-blockers repurposing within specific fields in oncology. Taken
all together, in fact, studies of β-blockers in cancer are in favor of these
agents as a new attractive and inexpensive therapeutic strategy in pa-
tients with several types of cancer. Given these persuasive options,
further dedicated prospective, randomized, placebo-controlled studies
are needed to determine the real efficacy of these compounds.
4.2. β-blockers and migraine
4.2.1. Headache, migraine: dimensions of the problem
Migraine and head pain are the fifth leading cause of emergency
department visits and top twenty reasons for outpatient visits in the
United States [51]. Its prevalence is estimated to 16% in the general
population and is more common in women (with a ratio of 3:1). More
than one-in-three persons who have episodic migraines would benefit
from prophylactic therapy: however, only 3%–13% manage to receive it
and obtain a satisfactory symptom control [52]. This condition nega-
tively affects health-related quality of life and begets depressive
symptoms irrespective of age, gender and level of education [53]. The
pharmacologic treatment of migraine may be acute (abortive) or pro-
phylactic, and patients with frequent severe headaches may require
both. Prophylactic therapy should be used to reduce the frequency,
duration, or severity of attacks: success of preventive therapy is defined
as a 50% reduction in attack frequency or headache days, a significant
decrease in attack duration, or an improved response to acute medi-
cation [54].
Being a chronic condition, once the need for prophylactic treatment
is established, therapy should be tailored considering comorbid condi-
tions in order to avoid exacerbate or worsen coexistent illnesses.
4.2.2. β-blockers and migraine pathophysiology
β-blockers are the most widely used class of drugs in prophylactic
migraine treatment and are about 50% effective in producing a greater
than 50% reduction in attack frequency [55]. However, the patho-
physiology of migraine and the mechanisms of action of β-blockers in
migraine prevention are not yet completely understood. Migraine is
predominantly a neurogenic rather than a vascular disorder and β-
blockers like metoprolol and propranolol appear to be efficaciousTa
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because they cross the BBB, exploiting their lipid solubility and modify
neuronal excitability via [56,57] (Table 3). β-1 receptor antagonism
seems to modulate cortical information processing expressed as changes
in visual evoked potentials (VEP) mediated through adrenaline and
noradrenaline, contingent negative variation (CNV), and auditory
evoked potentials (AEP), which are typically abnormal in patients with
migraine [58]. Indeed, in patients treated with β-blockers, the VEP
amplitude tends to normalize [59,60].
It has been shown that both metoprolol and propranolol normalize
CNV and that normalization of high CNV correlated positively with
treatment response [61,62]. Similarly, β-blockade with metoprolol and
bisoprolol decreased the dependence of evoked cortical potentials on
the intensity of auditory stimuli in migraine patients, and such a de-
crease was associated to clinical improvement [63]. All this evidence
suggests that β-blockers modulate cortical excitability and abnormal
cortical information processing in migraine.
In addition to their β-blocking action, however, propranolol and
timolol have high affinity for 5-hydroxytryptamine (serotonin or 5-HT)
receptors, namely 5HT2B and 5HT2C, which play a pivotal role in the
pathophysiology of migraine via 5-HT synthesis. Propranolol alone also
inhibits nitric oxide production by blocking inducible nitric oxide
synthase (NOS) potentially downregulating the activation of the trige-
minovascular complex [64,65]. Interestingly, it has been shown that β-
blockers with intrinsic sympathomimetic activity (i.e., acebutolol, ox-
prenolol, pindolol) are not as effective in migraine prevention. More-
over, propranolol interferes with the pharmacokinetics of rizatriptan, a
commonly prescribed triptan used in the treatment of migraine, re-
quiring important dose adjustment. Such effect however, is not ob-
served with metoprolol [66].
As a result, for the American Headache Society/American Academy
of Neurology guidelines (AHS/AAN) and for European Federation of
Neurological Societies (EFNS) among β-blockers propranolol, meto-
prolol, and timolol are considered level A drugs (Medications with es-
tablished efficacy with more than 2 Class I trials) and nadolol is con-
sidered a level B drugs (Medications that are probably effective with
one Class I or two Class II Studies) for the prophylaxis of episodic mi-
graine. Similar strong recommendations are present in the Canadian
Headache Society (CHS) guidelines. (Table 4) [55,67,68] (Table 3).
4.2.3. Level A β-blockers
4.2.3.1. Propranolol. Propranolol, together with metoprolol, is one of
the two β-blockers that are given the highest rating (level A) in practice
AHS/AAN, CHS, and EFNS guidelines. It is highly lipophilic and
therefore it can cross the blood-brain barrier. Compared to other β-
blockers but similarly to metoprolol, the benefits of propranolol appear
to be dose-dependent. At relatively low doses of each drug (50mg
topiramate vs. 80mg propranolol daily), topiramate results more
effective than propranolol [70]. Conversely, a higher dose of
propranolol (160mg daily) has effects similar to those obtained with
1–2mg/kg daily of topiramate in terms of responders rate and
reduction in migraine frequency, migraine days, and daily rescue
medication usage [71]. Propranolol and metoprolol appear similarly
effective in controlling migraines; however, the side effect profile of
metoprolol appears more favorable [72]. Compared with timolol,
propranolol is equally effective and with a similar CNS side effect
profile [73].
4.2.3.2. Metoprolol. Together with propranolol, metoprolol is the other
β-blocker with the highest level of evidence across major migraine
guidelines. Pharmacologically, it is a moderate lipophilic β-1 selective
agents, without affinity to 5-HT receptors.
Metoprolol has been shown to be more effective than placebo in
migraine prophylaxis [74,75]. As for propranolol, its effects are dose-
dependent, with 100mg twice daily being mostly effective [76]. As
mentioned above, metoprolol appears to have similarly effective as
propranolol, but with fewer side effects; to date, no studies have com-
pared the efficacy of metoprolol with other “level A” migraine pro-
phylactic medications in the AAN/AHS guidelines. Moreover, specific
formulations of metoprolol are also without specific allergens, i.e. lac-
tose and gluten, thus allowing chronic therapy also in allergic subset of
patients.
4.2.3.3. Timolol. Timolol has good affinity for 5-HT2B and 5HT2c
receptors, a property that makes it susceptible to potential
interactions with other serotonergic drugs. Timolol at a dose of
10–15mg twice daily is effective when compared to placebo, and
about equally effective as propranolol, in decreasing headache
frequency, with similar side effect profile [77].
4.2.4. Level B β-blockers
4.2.4.1. Nadolol. Nadolol is a hydrophilic β-blocker and does not cross
the BBB as easily as the other lipophilic compounds. This may prove
convenient as it may cause fewer central nervous system side effects
such as insomnia and mood depression. Given its longer half-life, unlike
propranolol and metoprolol, it allows a single daily dose, which may
translate into better adherence [78]. Nadolol was superior to placebo
for migraine prophylaxis [59]. However, when comparing 160mg
nadolol daily with 80mg propranolol twice a day, propranolol was
superior in terms of symptom control.
5. β-blockers in specific patient subset: Diabetes and Obstructive
Airway Diseases
However, concerns have been raised regarding the use of β-blockers
in the diabetic population due to a possible deteriorating metabolic
influence and the risk of prolonged hypoglycemia was hypothesized to
be higher with non-selective b-blockade in patients using insulin or
sulfonylureas [79]. However, no significant difference could be seen in
the risk of hypoglycemia with b-blockers in a cohort of 13,559 elderly
patients with DM compared with non-users. Only a non-significant
trend favoring cardioselective over non-selective b-blockers was regis-
tered [80].
Another subset of patients that warrants a specific attention when a
β-blockers is prescribed is represented by Chronic Obstructive
Pulmonary Disease (COPD) patients. Recommendations from the Global
Initiative for COPD (GOLD), hypertension, HF, CAD, and AF should be
Table 4
β-blockers for prevention of episodic migraine.
Drug AHS/AAN Guidelines CHS Guidelines EFNS Guidelines Dose β-blockers specific accessory mechanisms
Propranolol A Strong, high-quality evidence A 120−240mg a day Affinity to 5HT2B and 5HT2C receptors
Inhibition of inducible nitric oxide synthase
Metoprolol A Strong, high-quality evidence A 25 - 100mg twice daily
Timolol A Not rated Not rated 10−15mg twice daily Affinity to 5HT2B and 5HT2C receptors
Nadolol B Strong, moderate evidence B 80−160mg a day
AHA/AND: American Headache Society/American Academy of Neurology; CHS: Canadian Headache Society; EFNS: European Federation of Neurological Societies;
Level A: established as effective and should be offered to patients requiring migraine prophylaxis; Level B: probably effective and should be considered for patients
requiring migraine prophylaxis.
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treated according to usual guidelines even in patients with severe
COPD. If β-blockers are indicated, a selective β1-blocker (i.e., biso-
prolol, metoprolol, or nebivolol) should be chosen and non-selective
blockers avoided, especially in higher doses [81]. The ESC guidelines
for HF also encourage the use of selective β1-blockers in HF with COPD
[82]. The Global Initiative for Asthma (GINA) recommendations do not
encourage the use of b-blockers in patients with bronchial asthma; if
necessary, treatment should be started under close medical supervision
and decisions made on a case-by-case basis (level D evidence). Asthma
is not an absolute contraindication for cardioselective b-blockers for
acute coronary events, but a careful risk–benefit assessment should be
undertaken (level D evidence) [83]. However, a Cochrane review of 29
RCTs of cardioselective β1- blockers found no adverse respiratory ef-
fects in the short term in mild-moderate reversible airway disease or
COPD [84].
6. Conclusions
β-Blockers are an essential class of cardiovascular medications for
reducing morbidity and mortality in various cardiac conditions
(Table 4). Their use in the treatment of hypertension has been ex-
tensively debated and at the moment a class indication is not present.
However, in specific niche of patients, such as in those young in-
dividuals in which hypertension is mainly driven by a sympathetic
hyperactivation, strong evidence pose β-Blockers as a highly reasonable
first-line treatment. Because of the role in sympathetic outflow of the
cardio-regulatory and vasomotor centers of medulla oblongata, which
are activated by β-1 stimulation, moderate lipophilic β-blockers that
cross the BBB and inhibit the discharge of these neural structures might
be more suitable for this class of hypertensive patients. Moreover, after
more than 50 years from their discovery, new evidence is emerging,
suggesting their protective effect beyond the cardiovascular system. β-
Blockers, specifically propranolol and metoprolol have a Class A in-
dication for the prophylactic treatment of migraine attacks. More in-
terestingly, since β-adrenergic receptors affect the proliferative process
of both cancer and immune cells, their blockade has been associated
with metastasis reduction in several epithelial and solid organ tumors
(Table 4). All this data collectively support the idea of β-blockers re-
purposing within specific fields in oncology. However, whether β-
blockers in cancer represent a new attractive, inexpensive and rela-
tively safe therapeutic strategy in patients with several types of cancer,
further dedicated prospective, randomized, placebo-controlled studies
are needed to determine the real efficacy of these compounds.
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